Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for CytomX Therapeutics, Inc. (CTMX : NSDQ)

• Company Description    CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. Number of Employees: 121

• Price / Volume Information    Yesterday's Closing Price: $2.38 Daily Weekly Monthly 20 Day Moving Average: 1,954,313 shares Shares Outstanding: 80.62 (millions) Market Capitalization: $191.88 (millions) Beta: 2.05 52 Week High: $3.10 52 Week Low: $0.40 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 12.80% 7.13% 12 Week 210.79% 170.68% Year To Date 131.07% 115.81%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 151 OYSTER POINT BLVD.SUITE 400 - SOUTH SAN FRANCISCO,CA 94080 USA ph: 650-515-3185 fax: 650-351-0353 ir@cytomx.com http://www.cytomx.com

• General Corporate Information    Officers Sean A. McCarthy - Chief Executive Officer and Chairman Christopher W. Ogden - Chief Financial Officer Matthew P. Young - Director Alan Ashworth - Director Elaine V. Jones - Director Peer Information CytomX Therapeutics, Inc. (CORR.) CytomX Therapeutics, Inc. (RSPI) CytomX Therapeutics, Inc. (CGXP) CytomX Therapeutics, Inc. (BGEN) CytomX Therapeutics, Inc. (GTBP) CytomX Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 23284F105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 80.62 Most Recent Split Date: (:1) Beta: 2.05 Market Capitalization: $191.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.07 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.05 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: 4.96 PEG Ratio: - Price Ratios Price/Book: 7.66 Price/Cash Flow: 6.58 Price / Sales: 1.30 EPS Growth vs. Year Ago Period: 58.82% vs. Previous Quarter: 22.73% Sales Growth vs. Year Ago Period: 22.80% vs. Previous Quarter: 33.66% ROE 06/30/25 - - 03/31/25 - -553.71 12/31/24 - -147.04 ROA 06/30/25 - - 03/31/25 - 32.21 12/31/24 - 21.16 Current Ratio 06/30/25 - - 03/31/25 - 1.73 12/31/24 - 1.25 Quick Ratio 06/30/25 - - 03/31/25 - 1.73 12/31/24 - 1.25 Operating Margin 06/30/25 - - 03/31/25 - 28.22 12/31/24 - 23.11 Net Margin 06/30/25 - - 03/31/25 - 28.22 12/31/24 - 23.11 Pre-Tax Margin 06/30/25 - - 03/31/25 - 28.35 12/31/24 - 23.24 Book Value 06/30/25 - - 03/31/25 - 0.31 12/31/24 - -0.01 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - -

Powered by Zacks Investment Research ©